Quince Therapeutics, Inc.
QNCX
$34.04
$1.635.03%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 338.94% | -216.73% | -144.76% | 42.12% | -34.81% |
| Total Depreciation and Amortization | 12.50% | 143.75% | -58.14% | -20.45% | -20.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,331.17% | 449.85% | 292.95% | -68.23% | -6.04% |
| Change in Net Operating Assets | -216.04% | 558.05% | 227.63% | -31.65% | 354.78% |
| Cash from Operations | 20.56% | -38.78% | -36.75% | -30.62% | -14.94% |
| Capital Expenditure | -- | 96.99% | -60.87% | -223.08% | -279.49% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 8.64% | -26.59% | -123.87% | 224.82% | 23.38% |
| Cash from Investing | 10.11% | -25.73% | -125.07% | 221.31% | 22.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 17,127.59% | -- | -- | 41,077.14% | -54.21% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 10,754.02% | -- | 127.52% | 41,077.14% | -54.21% |
| Foreign Exchange rate Adjustments | -935.43% | -220.27% | 31.67% | 107.88% | -43.55% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 692.43% | -118.18% | -98.93% | 165.04% | 46.94% |